Podcasts about mbchb

On this episode of Diabetes Connections In the news… The ADA conference controversy continues with a boycott now, new patch pump approved, an update on long running research to reverse type 1, plus consensus guidelines on T1D screening, intermittent fasting for type 1, a new surprising study about COVID and T1D, statins, type 2 and dementia, and lots more..  This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.  Want to let you know about a webinar I'm doing with Abbott later this month. That's Sept 23 at 7pm ET. We'll be talking about ketones, DKA and learn more about their dual CGM/ketone monitor that was just approved. Join us for a webinar September 23 Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Transcript: On this episode of Diabetes Connections In the news… The ADA conference controversy continues with a boycott now, an update on long running research to reverse type 1, plus consensus guidelines on T1D screening, intermittent fasting for type 1, a new surprising study about COVID and T1D, statins, type 2 and dementia, and lots more.. It's all coming up right after this. (AD BREAK) Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. We are off to Detroit this week for Moms' Night Out in Bloomfield Michigan. Super excited and as usual I'm getting last minute emails and DMs about respiration from people just finding out about the event. We will always figure it out so drop me a line. But please register now for Seattle next month! Tampa will be open soon as well! Want to let you know about a webinar I'm doing with Abbott later this month. That's Sept 23 at 7pm ET. We'll be talking about ketones, DKA and learn more about their dual CGM/ketone monitor that was just approved. Great crowd already registered for that, hope you can join us. The link is in the show notes. Okay.. our top story this week: XX Member of the American Diabetes Association… are now boycotting it. The notice of the boycott condemns leadership's actions after five researchers were removed by police from its annual meeting in June. Significantly, The editors of ADA's flagship journal, Diabetes Care, have joined on in support of the boycott. "Manuscripts submitted will not be handled until the boycott is over," said Steven Kahn, MBChB, the journal's editor in chief and one of the five researchers ejected from the meeting in New Orleans, in a LinkedIn post on Thursday. Kahn told MedPage Today that "the journal boycott is like establishing a picket line. The boycott already has hundreds of signatures of people who have pledged to suspend all ADA-related activities, including: Planning or attending any meetings led by ADA leadership or the board, including the 2027 ADA Scientific Sessions Participating in board-led activities regarding the investigation of the meeting's events, or the report generated by the "so-called 'independent' committee" Engaging in all other ADA operations, including presentations, fundraisers, grant reviews, manuscript reviews, journal management, manuscript submissions, and position statements The boycott will remain active until the ADA board of directors permits an independent formal review of the organization's structure and function to ensure it "properly represent[s] its professional membership." If demands are not met, signees plan to align with existing or newly formed medical societies. https://www.medpagetoday.com/endocrinology/diabetes/122977 https://docs.google.com/forms/d/e/1FAIpQLSd4h548X9qXgkVREQ71k2gDHiU8WFAFF78wTnmS20_ntwUM0w/viewform XX A new patch pump is coming to the US.. Beta Bionics, Inc. announces FDA clearance of Mint, the Company's patch pump featuring a transformative reusable and disposable architecture that does not require recharging, integrates with industry-leading continuous glucose monitors (CGM) and enables smartphone control for iOS and Android users. The Company expects to initiate the full commercial launch of Mint in the United States in the first quarter of 2027 Mint is expected to launch exclusively through the pharmacy channel. Also announced, that Eversense 365 is now compatible with Beta Bionics Senseonics expects development of the Eversense 365-iLet integration to be completed during the fourth quarter of 2026. Commercial launch is planned following completion of integration activities in the fourth quarter of 2026, subject to required testing, validation activities and applicable regulatory requirements. No word yet on timing for Eversense with Mint. https://www.manilatimes.net/2026/09/14/tmt-newswire/globenewswire/beta-bionics-announces-fda-clearance-of-mint-the-companys-transformative-patch-pump-and-unveils-3d-intelligence-as-its-next-generation-insulin-dosing-algorithm/2424457 XX Seven years after Johns Hopkins researchers discovered a previously unknown immune cell called the "X cell," they're now exploring whether that discovery could lead to a new treatment for type 1 diabetes. In preclinical studies, researchers developed an antibody that was able to target and eliminate specific immune cells responsible for attacking the pancreas's insulin-producing beta cells, while leaving the rest of the immune system intact. The researchers say the approach is especially promising because it could potentially reverse the autoimmune process soon after a type 1 diabetes diagnosis, rather than simply managing blood sugar. The work is still in the early stages and has not yet been tested in people; additional laboratory and preclinical studies are needed before human clinical trials can begin. sclerosis.https://hub.jhu.edu/2026/09/09/federal-funds-support-type-1-diabetes-treatment/ XX A new international consensus recommends routine screening for type 1 diabetes in the general population, offering the first framework for how healthcare providers could put widespread screening into practice. The guidance recommends screening children between ages 2 and 4, with children who test negative screened again at ages 6–8 and 10–15. Screening uses a blood test to look for islet autoantibodies, which can signal that the immune system is attacking insulin-producing cells years before symptoms appear or insulin is needed. Finding type 1 diabetes early can greatly reduce the risk of diabetic ketoacidosis, or DKA, at diagnosis and may give people access to treatments such as teplizumab that can delay progression to clinical T1D. https://www.prnewswire.com/news-releases/breakthrough-t1d-convened-paper-outlines-first-international-consensus-guidance-on-general-population-screening-for-early-stage-type-1-diabetes-302875788.html   XX Eating only between noon and 8 p.m. improved blood sugar control in a small study of adults with Type 1 diabetes and obesity, while avoiding an increase in serious complications. The promising findings offer the first evidence that time restricted eating could become another tool for managing the condition. For the study, Varady recruited adults with Type 1 diabetes who were also classified as obese After six months, the time-restricted eating group showed better blood sugar results than the calorie-reduction group. HbA1c, a blood test that reflects average blood sugar over the previous several months, fell by about 0.5% on average in the time-restricted group.   Couple of things here – very small study, only 32 people in total, who were then randomly placed in three groups with different styles of eating. Also, the lead researcher says this is the first study of it's kind for type 1 – which is obviously not true – you can do a quick google search or listen to past episodes of this show.. https://www.sciencedaily.com/releases/2026/09/260909231740.htm XX A large Danish study found that COVID-19 infection was associated with a slightly lower, rather than higher, risk of subsequently developing type 1 diabetes in people under age 30. Researchers studied more than 2,100 people diagnosed with T1D and found an overall 16% lower risk following a documented COVID infection, with the strongest association—a 42% reduction—seen 31 to 180 days after infection. The reduced risk appeared primarily among people who had not been vaccinated against COVID-19, although researchers cautioned that the vaccination findings were less certain. Importantly, this was an observational study, so it cannot show that COVID infection actually protects against type 1 diabetes or explain what caused the association. Researchers say the findings conflict with some earlier studies and should be investigated in other countries and populations. https://www.news-medical.net/news/20260908/COVID-19-linked-to-lower-subsequent-risk-of-type-1-diabetes.aspx   XX   Semaglutide, a medication widely used for type 2 diabetes and weight loss, may also provide an unexpected benefit for people with asthma. New research presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain, found that semaglutide use was associated with a reduction in asthma attacks of nearly 40%.   The study was led by Professor Chloe Bloom, Clinical Associate Professor in Respiratory Epidemiology at the National Heart & Lung Institute, Imperial College London, UK, and presented by Dr. Bohee Lee.       Exploring GLP 1 Drugs and Lung Health   Dr. Bloom said: "GLP-1 receptor agonists are widely used to treat type 2 diabetes and obesity. Previous research suggests that they may have anti-inflammatory effects and may improve lung-related outcomes. However, asthma and COPD outcomes have not been included as outcomes in GLP-1 drug trials.   "We wanted to use real-world health records to investigate whether people with asthma or COPD who started GLP-1 receptor agonists had fewer acute respiratory attacks."   To investigate that question, the researchers analyzed electronic medical records from the UK. They carried out four parallel studies, each involving between 20,000 and 22,000 people who had started treatment with either a GLP-1 medication or a different type of diabetes drug known as a sulfonylurea.   The results suggested that people with airway diseases such as asthma and COPD who received GLP-1 therapies experienced fewer asthma attacks and COPD flare-ups than comparable patients who were prescribed other diabetes medications.   Semaglutide Showed the Strongest Effect   Among the GLP-1 drugs examined, semaglutide appeared to stand out, particularly for people with asthma.   Bloom explains: "The effect was strongest with semaglutide, especially in people with asthma, where use of semaglutide appears to be associated with nearly a 40% reduction in asthma attacks. Semaglutide also led to a 20% reduction in COPD flare-ups."   The findings suggest that people who already qualify for GLP-1 receptor agonists because they have obesity or type 2 diabetes could potentially receive an additional benefit for their respiratory health.   However, Bloom emphasized that the results are not enough to recommend these medications specifically as treatments for asthma or COPD.   She explains: "The findings from this study are encouraging, but they should not change treatment decisions on their own. People with asthma or COPD should not start GLP-1 receptor agonists specifically for their lung condition outside current prescribing guidance. While the findings suggest that some people taking GLP-1 receptor agonists may experience fewer respiratory attacks, this needs confirmation in clinical trials." https://www.sciencedaily.com/releases/2026/09/260909005155.htm XX XX A large study suggests women with endometriosis may have a higher risk of developing type 2 diabetes. Researchers analyzed health records from nearly 3 million women in Utah and found those diagnosed with endometriosis were 46% more likely to develop type 2 diabetes than those without the condition. The association was strongest among women who had not yet reached menopause and those without obesity, a group typically considered at lower risk for type 2 diabetes. Certain forms of endometriosis, including those found outside the pelvic area, were associated with more than twice the risk. Researchers say more study is needed, but the findings suggest endometriosis may have health effects beyond the reproductive system and could eventually help identify women who may benefit from earlier diabetes screening. https://www.nih.gov/news-events/nih-research-matters/endometriosis-may-increase-type-2-diabetes-risk   XX MiniMed files FDA submission for it's first patch pump, with a planned launch next summer. To be called MiniMed fit, it would have a 300-unit insulin reservoir and would accommodate up to seven days of wear time. MiniMed also completed enrollment of a pivotal trial for a fully closed loop algorithm, which would calculate the amount of insulin a person needs throughout the day, even if they don't announce meals or count carbohydrates. Interestingly, on an investor call, the CEO acknowledged that CGMs have been their – quote – Achilles' heel for a very long time" and that their newest sensor has helped drive insulin pump growth. https://www.medtechdive.com/news/minimed-submits-new-patch-pump-for-fda-clearance/829313/ XX A new study based on national health registers in Denmark suggests starting statin treatment after a type 2 diabetes diagnosis could lower the risk of dementia, and it seems that the sooner patients did, the better. The research, published in The Lancet Regional Health, is an observational study, meaning it can find statistically relevant patterns at the population level, but doesn't necessarily explain what caused those patterns. The results, however, were interesting enough that the researchers, led by medical doctor Tummas Ternhamar of the Copenhagen University Hospital, are urging doctors to consider statin therapy when diagnosing type 2 diabetes patients. "Statins seem to be underused in patients with type 2 diabetes, despite their protective effects against cardiovascular disease." https://www.sciencealert.com/statins-linked-to-lower-dementia-risk-in-massive-type-2-diabetes-study XX Big sports news with type 1. Alezander Zverev wins Family was at the heart of Alexander Zverev's U.S. Open triumph on Sunday as the German saluted the members of his inner circle and paid a heartfelt tribute to his mother for refusing to let diabetes define his future. The ​top seed beat American Ben Shelton 6-3 7-6(2) 5-7 6-2 at Flushing Meadows to finish a spectacular year at ‌the Grand Slams in which he proved his doubters wrong by going from perennial nearly man to two-time major champion. Shortly after his victory, Zverev reserved special praise for his mother Irina, a former professional tennis player, and credited her with ensuring type 1 diabetes never limited his ambitions in life. "When your 4-year-old son is diagnosed with diabetes and doctors in the office ​tell you that life and sports will be very limited for that child, it takes a very strong mother to ​say 'my son will be whatever he wants to be'," Zverev said. "'If he wants to be a tennis player, ⁠he'll be a tennis player. If he wants to do something else, he'll do something else, but this illness will not define us'. https://www.reuters.com/sports/tennis/zverev-hails-mothers-belief-after-us-open-triumph-2026-09-13/ XX Also, shout out to Garrett Mitchell (Center field  Milwaukee Brewers) lives with Type 1 Diabetes and hit a grand slam immediately after having a failed insulin pump site. He was diagnosed with T1D at the age of 9. And I have a T1d mom friend who's known him since he was a kid. Just great to see athletes talking about failed insulin sets like they're just part of everyday life.. because they are. Btw it was the first grand slam for the brewers all year. XX The new Netflix movie The Runner is getting a bit of a side eye from some in the diabetes community… the Gal Gadot thriller features a child with type 1 but as usual, there are some weird inaccuracies. Ginger Vieria from Diabetes nerd has a great vide on this – I'll link it up: but they're saying things like Insulin Dispenser instead of pump.. and some other weird stuff.. but I've heard such bad things about this movie I'm not sure it's worth watching just for this. Ginger's video is though! https://www.youtube.com/shorts/o8cw_gEZj5s  

In this podcast, featuring audio from a live webinar, experts Claudia P. Cortes, MD, and Chloe Orkin, MBChB, FRCP, MD, explore advancements in HIV prevention and treatment presented at the 26th International AIDS Conference (AIDS 2026). To download the accompanying slides and view more conference coverage, visit the program page. Topics covered include: New clinical trial and real-world data for available and emerging initial antiretroviral therapy (ART) regimens for people living with HIV Long-acting options for ART and HIV pre-exposure prophylaxis (PrEP). Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters:Claudia P. Cortes, MD Full Professor Director for Centre for HIV AIDS Integral Research – CHAIR Universidad De Chile Santiago, Chile Chloe Orkin, MBChB, FRCP, MD Professor of Infection and Inequities Dean for Healthcare Transformation Faculty of Medicine and Dentistry Queen Mary University of London Honorary Consultant Physician, Barts Health NHS Trust London, United Kingdom Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Martina McGrath, MBChB, FASN, Ihab Michel Wahba, MD, FASN, and Amir Kazory, MD, FASN, join guest Ashish Upadhyay, MD, and Sushrut S. Waikar, MD, MPH, to discuss "AKI in 2026: Emerging Evidence and Evolving Clinical Practice," from nephSAP Vol. 25, No. 2.

Martina McGrath, MBChB, FASN, Ihab Michel Wahba, MD, FASN, and Amir Kazory, MD, FASN, join guest Ashish Upadhyay, MD, and Sushrut S. Waikar, MD, MPH, to discuss "AKI in 2026: Emerging Evidence and Evolving Clinical Practice," from nephSAP Vol. 25, No. 2.

In this special episode hosted by the AOFAS Young Physicians Committee and EFAS Youth Committee, AOFAS surgeons Matt Conti, MD, and Sara Galli, MD, join EFAS surgeons Amit Patel, MBBS, BSc, MSc FRCS, and Tom Lewis, MBChB, BSc, MFSTEd, FRCS, PhD, to discuss Hallux Rigidus treatment options. Stay tuned for the conclusion of this 2-part series.   For additional educational resources, visit AOFAS.org

 There has been a sharp spike in silicosis diagnoses among workers who work with engineered stone countertops. The ATS released a report in 2026 on the subject, “Silicosis in the Artificial Stone Countertop Industry: An Official American Thoracic Society Workshop Report”. One of the report's authors Kristin Cummings, MD, MPH, California Department of Public Health, and expert Maeve McMurdo, MBChB, Cleveland Clinic, discuss why engineered stone can cause severe, rapidly progressive lung disease in young workers as well as the limitations of current workplace protections. On this episode of the ATS Breathe Easy podcast, they also highlight safer alternatives, the importance of recognizing occupational exposures, and what clinicians, employers, and consumers can do to help protect workers. Important resources: Read the full ATS report: https://pubmed.ncbi.nlm.nih.gov/42363709/ Failure of wet methods to control silica exposures: Soo et al. Respirable dust and respirable crystalline silica exposures among workers at stone countertop fabrication shops in Georgia from 2017 through 2023: https://pubmed.ncbi.nlm.nih.gov/40249150/ Prevalence of silicosis among Australian countertop workers: Hoy et al. Prevalence and risk factors for silicosis among a large cohort of stone benchtop industry workers https://pubmed.ncbi.nlm.nih.gov/37328266/Rapid progression of artificial stone silicosis after exposure cessation: Leon-Jimenez et al. Artificial Stone Silicosis: Rapid Progression Following Exposure Cessation: https://pubmed.ncbi.nlm.nih.gov/32563682/ California engineered stone silicosis dashboard (updated weekly): https://www.cdph.ca.gov/Programs/CCDPHP/DEODC/OHB/Pages/essdashboard.aspx 

Sarah Aitken, MBChB, PhD describes how identifying some very specific mutations can help identify drugs that can be used to make treatment of cancer care more personalized and more precise. Yale Cancer Center Visit: https://medicine.yale.edu/cancer/ Email: canceranswers@yale.edu Call 203-785-4095

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUQ865. CME/MOC/EBAH/NCPD/CPE/AAPA credit will be available until July 9, 2026.Rethinking the CLL Treatment Sequence: Guidance on Selecting and Sequencing Modern Treatment for Sustained Efficacy Across Lines of Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Chronic Lymphocytic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUQ865. CME/MOC/EBAH/NCPD/CPE/AAPA credit will be available until July 9, 2026.Rethinking the CLL Treatment Sequence: Guidance on Selecting and Sequencing Modern Treatment for Sustained Efficacy Across Lines of Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Chronic Lymphocytic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUQ865. CME/MOC/EBAH/NCPD/CPE/AAPA credit will be available until July 9, 2026.Rethinking the CLL Treatment Sequence: Guidance on Selecting and Sequencing Modern Treatment for Sustained Efficacy Across Lines of Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Chronic Lymphocytic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUQ865. CME/MOC/EBAH/NCPD/CPE/AAPA credit will be available until July 9, 2026.Rethinking the CLL Treatment Sequence: Guidance on Selecting and Sequencing Modern Treatment for Sustained Efficacy Across Lines of Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Chronic Lymphocytic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

Martina McGrath, MBChB, FASN; Jean Francis, MD, FASN; Ihab Michel Wahba, MD, FASN; and Amir Kazory, MD, FASN, speak with guest editor Biff F. Palmer, MD, to discuss his editorial on Hypernatremia from nephSAP Volume 25, Number 1. 

Martina McGrath, MBChB, FASN; Jean Francis, MD, FASN; Ihab Michel Wahba, MD, FASN; and Amir Kazory, MD, FASN, speak with guest editor Biff F. Palmer, MD, to discuss his editorial on Hypernatremia from nephSAP Volume 25, Number 1. 

In this episode of ASTCT Talks, Dr. Nirali Shah talks with Dr. Cath Bollard as part of the Titans of Transplant series to explore her remarkable career journey and lasting impact on the field of transplantation and cellular therapy. From early inspirations rooted in personal experience to her leadership in advancing cell therapy, Dr. Bollard reflects on her decades of experience across research, clinical care, and mentorship. The conversation highlights both the scientific progress in cellular therapies and the human stories that continue to drive innovation. Dr. Bollard also shares insights into the challenges of building a career as a physician-scientist and the importance of passion, resilience, and collaboration in advancing the field.Tune in for a conversation that covers:Dr. Bollard's path into pediatric hematology/oncology and the personal experiences that shaped her focus on immunotherapy.Key milestones in the evolution of cell therapy, including early translational work and the path to broader adoption.Ongoing challenges in treating diseases like AML and pediatric solid tumors.The importance of mentorship, team science, and developing the next generation of leaders.Reflections on balancing a demanding career with her personal life and staying grounded in purpose.Listen to the episode below or on your favorite app. Subscribe to ASTCT Talks and share this episode with your colleagues to keep the conversation going.

Carel le Roux, MBChB, MSc, PhD - Beyond BMI: Transforming Modern Weight Management for Heart, Kidney, and Metabolic Health

Carel le Roux, MBChB, MSc, PhD - Beyond BMI: Transforming Modern Weight Management for Heart, Kidney, and Metabolic Health

Carel le Roux, MBChB, MSc, PhD - Beyond BMI: Transforming Modern Weight Management for Heart, Kidney, and Metabolic Health

Carel le Roux, MBChB, MSc, PhD - Beyond BMI: Transforming Modern Weight Management for Heart, Kidney, and Metabolic Health

Carel le Roux, MBChB, MSc, PhD - Beyond BMI: Transforming Modern Weight Management for Heart, Kidney, and Metabolic Health

Carel le Roux, MBChB, MSc, PhD - Beyond BMI: Transforming Modern Weight Management for Heart, Kidney, and Metabolic Health

Carel le Roux, MBChB, MSc, PhD - Beyond BMI: Transforming Modern Weight Management for Heart, Kidney, and Metabolic Health

Carel le Roux, MBChB, MSc, PhD - Beyond BMI: Transforming Modern Weight Management for Heart, Kidney, and Metabolic Health

In this episode of Joint Ventures, host Rihards Buss, MD, consultant rheumatologist, Freeman Hospital, Newcastle, sits down with Sarah Dyball, MBBS, PhD, academic clinical lecturer, Centre for Musculoskeletal Research, University of Manchester, and Kate Harnden, MBChB, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, at the European Alliance of Associations for Rheumatology (EULAR) 2026 annual congress in London.Click here to watch the episode.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Zarazuela Zolkipli-Cunningham, MBChB, MRCP Guest: Oscar H. (Hank) Mayer, MD Thymidine kinase 2 deficiency (TK2d) is a rare mitochondrial myopathy that can involve multiple organ systems, requiring care from different specialties. Given that need for multidisciplinary coordination, Dr. Charles Turck speaks with Drs. Hank Mayer and Zuela Zolkipli-Cunningham to learn how we can improve communication and collaboration across the care team throughout the diagnostic and management journey. Coming to us from the Children's Hospital of Philadelphia, Dr. Mayer is the Director of the Pulmonary Function Laboratory, and Dr. Zolkipli-Cunningham is the Director of Clinical Research in the Mitochondrial Medicine Frontier Program.

Burnout expert Dr Anton Janse van Rensburg is a practising medical doctor from Pretoria, South Africa, with 27 years of experience as an Integrative Practitioner. Besides his MBChB degree, he has a Master's degree in Applied Human Nutrition from the University of Pretoria, and an Advanced Management Diploma from Manchester Business School. He is also a trained metal toxicologist.His clinical practice focuses on burnout, mood disorders, adjuvant therapy for cancer patients, auto-immune disorders, severe intestinal conditions, and chronic infectious diseases.Summary of PodcastKey TakeawaysBurnout is a systemic depletion, not just fatigue. It results from neglecting many small, daily habits (rest, connection, diet), not just from overwork.Dr. Anton's method is prescriptive and holistic. It prioritises daily habits (e.g., 20-min power naps, strong connections) and uses comprehensive tests to find root causes before considering medication.Nutrition is a primary tool for managing chronic conditions. A high-fat, low-carb diet can reverse Type 2 diabetes and stabilise mood by reducing cravings for refined carbs and optimising brain chemistry.Purpose and challenge are critical for longevity. Complete retirement is a risk factor for rapid aging; staying engaged with meaningful work or new challenges is essential for maintaining brain health.Burnout: Root Causes & Holistic SolutionsDefinition: A systemic depletion from neglecting many small, interconnected daily habits (physiological, emotional), not just from overwork.Origin of Insight: Dr. Anton's experience managing health for 9,000 workers on a high-stress construction site in Maputo, Mozambique (2000–2003).This role involved diagnosing 30–40 malaria cases daily and managing fatalities, providing a "crossroads" experience that informed his later focus on burnout.Dr. Anton's Prescriptive Approach:Initial Assessment: A deep history of work hours, rest habits, and personal connections.Daily Respite: Prescribes short, scheduled breaks to manage the body's natural circadian dip.Power Naps: 20-minute naps are ideal; naps >1 hour are detrimental to brain health.Social Connection: Emphasises strong relationships with friends, family, and colleagues, citing research on their importance for resilience and longevity.Physiological Testing: Uses comprehensive tests (bloods, stress ECGs) to find root causes, not just manage symptoms.Kevin's Experience: Burnout led to "reduced performance"—sitting at the desk with a large to-do list but accomplishing nothing.Solution: Stepped away from the desk more often and re-prioritised tasks to reduce stress.Mood Disorders & The Role of NutritionDefinition: A broad term for unstable brain chemistry, which can manifest as sadness, cynicism, or even physical fatigue (e.g., heavy limbs, a known symptom of low serotonin).Societal Factors: Increased prevalence in younger generations is linked to social media exposure and a sedentary lifestyle, both of which negatively impact brain chemistry.Nutrition as a Primary Tool:Core Principle: The brain requires healthy fats (avocado, olive oil, nuts, meat) and is harmed by refined carbohydrates.Mechanism: A high-fat, low-carb diet reduces cravings for refined carbs, which drives illness and instability.Case Study (Mood Disorder): A patient with a severe mood disorder saw significant improvement within 48 hours of starting a high-fat, low-carb diet, avoiding hospitalization.Case Study (Type 2 Diabetes): A patient on metformin for 25 years was advised to challenge the medication's necessity.Process: A low-carb, high-fat diet for six months, monitored with fasting insulin and HbA1c tests, can reveal if the pancreas can function without medication.Outcome: If successful, medication can be slowly and carefully reduced.Calorie Counting: Dr. Anton strongly advises against restrictive diets and calorie counting, as they are unsustainable and against human nature.The Future of Work & PurposeAI's Impact: The potential for AI to eliminate jobs raises concerns about a loss of purpose and meaning, which are often tied to work and contribution.Retirement & Longevity: Dr. Anton cautions that complete retirement is a risk factor for rapid aging.Recommendation: Stay engaged with meaningful activities (consulting, volunteering, mentoring) to maintain brain health and purpose.Challenge: The brain, like a muscle, needs to be challenged to grow and stay healthy. Avoiding challenges is detrimental to long-term well-being.The Next 100 Days Podcast Co-HostsGraham ArrowsmithGraham founded Finely Fettled in 2014 to provide data from The UK High Net Worth Database to marketers targeting affluent and high-net-worth customers. He's the founder of MicroYES, a Partner for MeclabsAI, creating lead generation AI Agents & Workflows and introducing the MeclabsAI Platform. Graham also provides an Answer Engine Optimisation solution to get your website in shape to be found by LLMs.Kevin ApplebyKevin specialises in finance transformation and implementing business change. He's the COO of GrowCFO, which provides both community and CPD-accredited training designed to grow the next generation of finance leaders. You can find Kevin on LinkedIn and at kevinappleby.com

Guest: Carel le Roux, MBChB, MSC, FRCP, FRCPath, PhD New findings from the SYNCHRONIZE-1 trial reveal that survodutide's impact extends beyond weight reduction, with a demonstrated decrease in liver fat and meaningful improvements across multiple markers of metabolic health in patients without type 2 diabetes. Dr. Carel le Roux joins us to share the efficacy and safety data and explore what these results could mean for the future of metabolic disease management. Dr. Le Roux is the Director of the Metabolic Medicine Group and a Professor of Chemical Pathology in the School of Medicine at University College Dublin, and he presented these findings at the 2026 American Diabetes Association Scientific Sessions.

From ultra-processed foods and pesticides to environmental toxins, pharmaceuticals, and chronic disease, it can feel overwhelming to try to make sense of it all - - - especially when our health "authorities" seem to continuously change their minds about what's good for us and what's killing us - - - and everything seems to be poison now. In this eye-opening conversation, Jamie Belz, FNTP, MHC, sits down with veteran pediatrician, integrative physician, author, speaker, and health freedom fighter, and author Dr. Michelle Perro, MD, DHom, to discuss one of the biggest questions of today: How do we pursue true health in an increasingly toxic world? Drawing from more than four decades of clinical experience, Dr. Perro shares her perspective on the growing health challenges affecting children and adults alike, why so many people are searching for answers outside conventional approaches, and what practical steps individuals can take to reclaim their health. Together, Jamie and Michelle dive into topics including: • What's making our children sick and how we can begin making them well • Glyphosate, GMOs, fluoride, and environmental toxic burden • The MAHA (Make America Healthy Again) movement and why it continues to gain momentum • Why curiosity is one of the most important skills we can develop in today's world • The importance of critical thinking and informed decision-making • Finding trustworthy health information in an age of information overload • Lyme disease, chronic illness, and environmental health concerns • The role of food as the foundation of physical and mental wellness • Transhumanism, AI, technology, and the future of human health • Why community matters when pursuing a different path toward wellness • How young people can become empowered advocates for their own health • Why the choices we make today may impact future generations One of the most powerful themes throughout this conversation is the idea that health is often visible. Spend time around people who prioritize nutrient-dense food, clean water, movement, sunshine, meaningful relationships, and foundational wellness, and you'll often notice a difference. There is a vibrance, energy, resilience, and optimism that stands out. Jamie and Michelle discuss how surrounding yourself with people who value health can accelerate your own journey and help you stay the course when the path feels unconventional. Whether it's attending a health conference, joining a local Weston A. Price chapter, connecting with practitioners, or simply finding friends who share similar values, this episode highlights the importance of finding community and support as you pursue a healthier life. Most importantly, this conversation is a reminder that lasting change starts with paying attention. Asking questions. Staying curious. Learning to think critically. And taking ownership of the choices that shape your health and the future health of those around you. Please subscribe, leave a review, and share this episode! About Michelle Perro, MD Dr. Michelle Perro is a veteran pediatrician with more than 40 years of clinical experience caring for children and families. Formerly an attending physician at UCSF Benioff Children's Hospital Oakland, she has treated tens of thousands of patients throughout her career and has become a leading voice in children's environmental health. She is the founder and CEO of GMOScience and the co-author of the bestselling books What's Making Our Children Sick? and Making Our Children Well. Her work focuses on the connection between modern food systems, environmental exposures, chronic illness, and the long-term health of future generations. Dr. Perro regularly speaks internationally, educating parents, healthcare professionals, and communities about nutrition, environmental medicine, and informed healthcare choices. Dr. Michelle Perro's Books:  What's Making Our Children Sick?https://www.amazon.com/Whats-Making-Our-Children-Sick/dp/1603587578 Making Our Children Well GMOScience Other Resources Mentioned: Weston A. Price Foundation Find a Weston A. Price Local Chapter   S2E2: AI In the Kitchen S1E6: Dr. Francis M Pottenger Jr Story Health Revival Podcast Episode with Dr. Perro Jamie's "Scientific Advisory Council" or "SAC" (Copy/Paste/Store in Chat/Grok/Etc.) Del Bigtree Lindsey Berkson, DC, CNS William Burgdorfer, PhD Jill Carnahan, MD Ignacio Chapela, PhD Rangan Chatterjee, MBChB, MRCGP Alan Gaby, MD Michael Gerber Tyrone Hayes, PhD Jesse Inchauspé, BSc Mikhail Kogan, MD Patty Lemmer Elizabeth Lipski, PhD, CCN James Lyons-Weiler, PhD Peter McCullough, MD, MPH Jennifer McGruther Judy Mikovits, PhD Luc Montagnier, MD, PhD Candace Pert, PhD Michelle Perro, MD Francis M. Pottenger Jr., MD Weston A. Price, DDS Árpád Pusztai, PhD Robert F. Kennedy Jr., JD Jordan Rubin, NMD Gretchen Rubin, JD Sally Fallon Morell, MA Gilles-Éric Séralini, PhD Stephanie Seneff, PhD Troy Spurrill, MD Gerard Tortora, PhD Matthew Walker, PhD Jack Wolfson, DO, FACC  

In this World Shared Practice Forum Podcast, Drs. Mark Peters and Scott Weiss provide their expert insight on the methodology and development of the 2026 International Surviving Sepsis Campaign guidelines. They discuss challenges encountered during the process and review notable changes to these guidelines compared to previous iterations. The authors share the recommendations that will most impact their personal practice for patients with sepsis, and reflect on how we can improve global research infrastructure to address salient knowledge gaps in pediatric critical care. LEARNING OBJECTIVES - Understand the design and methodology for the 2026 Surviving Sepsis Campaign guidelines - Review notable changes in the 2026 sepsis guidelines compared to the 2020 edition - Discuss the implications of the altered recommendations for clinical practice changes - Consider methods to improve global pediatric research infrastructure and data organization AUTHORS Mark Peters, MBChB, PhD, MRCP, FFICM, FRCPCH Professor of Paediatric Intensive Care NIHR Senior Investigator UCL Great Ormond St Institute of Child Health Hon. Consultant Paediatric Intensivist Paediatric Intensive Care Unit and Children's Acute Transport Service Great Ormond St Hospital Scott Weiss, MD, MSCE Professor of Pediatrics and Pathology & Genomic Medicine, Division Chief of Critical Care, Vice-Chair of Research for the Department of Pediatrics, Nemours Children's Hospital, Sidney Kimmel Medical College at Thomas Jefferson University Jeffrey Burns, MD, MPH Emeritus Chief Division of Critical Care Medicine Department of Anesthesiology, Critical Care and Pain Medicine Boston Children's Hospital Professor of Anesthesia Harvard Medical School DATE Initial publication date: May 26, 2026. ARTICLES REFERENCED & ADDITIONAL REFERENCES - Weiss SL, Peters MJ, Oczkowski SJW, et al. Surviving Sepsis Campaign International Guidelines for the Management of Sepsis and Septic Shock in Children 2026. Pediatr Crit Care Med. 2026;27(4):379-434. https://pubmed.ncbi.nlm.nih.gov/41869844/ - Balamuth F, Weiss SL, Long E, et al. Balanced Fluid or 0.9% Saline in Children Treated for Septic Shock. N Engl J Med. Published online April 24, 2026. https://pubmed.ncbi.nlm.nih.gov/42028918/ - Weiss SL, Balamuth F, Long E, et al. PRagMatic Pediatric Trial of Balanced vs nOrmaL Saline FlUid in Sepsis: study protocol for the PRoMPT BOLUS randomized interventional trial. Trials. 2021;22(1):776. Published 2021 Nov 6. https://pubmed.ncbi.nlm.nih.gov/34742327/ - Steven Pinker "Enlightenment Now” - https://stevenpinker.com/publications/enlightenment-now-case-reason-science-humanism-and-progress - Blood Poison: The Untold Story of Sepsis - https://amplifypublishinggroup.com/product/nonfiction/health-medicine-and-wellness/general-health-medicine-and-wellness/blood-poison/ TRANSCRIPT https://cdn.bfldr.com/D6LGWP8S/at/r9q8w9vhsbpg7wwzn35kbmz/202605_WSP_Peters_and_Weiss_Transcript.pdf Please visit: http://www.openpediatrics.org OPENPediatrics™ is an interactive digital learning platform for healthcare clinicians sponsored by Boston Children's Hospital and in collaboration with the World Federation of Pediatric Intensive and Critical Care Societies. It is designed to promote the exchange of knowledge among healthcare providers worldwide who care for critically ill children across all resource settings. The content includes internationally recognized experts teaching the full range of topics on the care of critically ill children. All content is peer-reviewed and open-access, thus at no expense to the user. For further information on how to enroll, please email: openpediatrics@childrens.harvard.edu CITATION Peters MJ, Weiss SL, O'Hara J, Burns JP. Pediatric Surviving Sepsis: Insights From the Leadership. 05/2026. OPENPediatrics. Online Podcast. https://soundcloud.com/openpediatrics/pediatric-surviving-sepsis-insights-from-the-leadership-by-m-peters-s-weiss-openpediatrics.

The U.S. Food and Drug Administration recently qualified "total hip bone mineral density" as a surrogate endpoint to support clinical trials for osteoporosis drugs. This decision will significantly impact clinical trials moving forward, as the traditional endpoint of "fracture outcomes" presented many challenges regarding sample size, duration, and cost. The change came about because of findings from the study to advance bone mineral density as a Regulatory Endpoint Project, also known as the SABRE project.What is the SABRE project, and how did it arrive at these findings? How will this decision affect the design of clinical trials and time to approval of new osteoporosis therapies? To help answer these questions and many more, Host Aaron Lohr spoke with three leaders of the SABRE Project: Dennis M. Black, PhD, professor of epidemiology and biostatistics at the University of California, San Francisco; Richard Eastell, MBChB, PhD, FRCP, FMedSci, professor of bone metabolism at the University of Sheffield, and Mary L. Bouxsein, PhD, professor of orthopedic surgery at Harvard Medical School.

Listen in to learn the latest on ART switch strategies for people living with virologically suppressed HIV. Hear from experts Chloe Orkin, MBChB, FRCP, MD, and Peter J. Ruane, MD, as they review how the recent approvals fit in the treatment landscape of 2-drug, single-tablet regimens. Stream on the go or follow along with our expert-curated slides.  Topics covered include:  Guideline recommendations on ART switch in the setting of virologic suppression Phase III clinical trial data supporting ART switch Individual considerations for ART switch Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Chloe Orkin, MBChB, FRCP, MD Professor of Infection and Inequities Dean for Healthcare Transformation Faculty of Medicine and Dentistry Queen Mary University of London London, United Kingdom of Great Britain and Northern Ireland Honorary Consultant Physician Barts Health NHS Trust London, United Kingdom Peter J. Ruane, MD President Ruane Clinical Research Los Angeles, California Link to program page: https://bit.ly/3PkPoP4 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen now as experts, Chloe Orkin, MBChB, FRCP, MD, and Jihad Slim, MD, explore the potential clinical implications of new data on novel options for optimizing HIV therapy, especially for treatment-experienced people with challenges using currently available regimens, high pill burdens, and reduced adherence. Listen on the go or follow along with our expert-curated slides. Topics covered include: Current Options for Simplifying ART DHHS and EACS Recommendations for 2-Drug Regimens The Latest Results of the ARTISTRY-1 and -2 Trials Future Directions for HIV Therapy Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Chloe Orkin, MBChB, FRCP, MD Professor of Infection and Inequities Dean for Healthcare Transformation Faculty of Medicine and Dentistry Queen Mary University of London  Honorary Consultant Physician Barts Health NHS Trust London, United Kingdom Jihad Slim, MD Assistant Professor of Medicine New York Medical College Valhalla, New York Chief of Infectious Disease Saint Michael's Medical Center Newark, New Jersey Link to program page: https://bit.ly/4u31NGv Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send us Fan MailJoin our guest host, Ron El-Hawary, MD, MSc, as he speaks with members from the past and current L.E.A.D. cohorts, Christina K. Hardesty, MD (2023-24), Annalise Noelle Larson, MD (2024-25), and Morgan Jones, MBChB, BSc, Hons, MSc (2025-26). L.E.A.D. SRS is a leadership development program aimed at the next generation of leaders within the SRS. This year-long program provides a cohort of individuals the opportunity to gain a deeper understanding of the SRS and how to be an impactful leader.L.E.A.D. applications open this Friday, May 1, 2026! Learn more on our website HERE.*The Scoliosis Research Society (SRS) podcast is aimed at delivering the most current and trusted information to clinicians that care for patients with scoliosis and other spinal conditions. From news in the world of spinal conditions, to discussions with thought leaders in the field, we aim to provide up-to-date, quality information that will impact the daily practice of spinal conditions.

Host Praveen Ranganath, MD is joined by cohost Manish Motwani, MBChB, PhD, FSCCT to facilitate a panel discussion on artificial intelligence in cardiac imaging. Panelists:Damini Dey, PhD, FSCCTArthur Shiyovich, MDAlan Vainrib, MDMarly van Assen, MSc, PhD Resources:•Artificial Intelligence and Machine Learning for Cardiovascular Computed Tomography (CCT): A White Paper of the Society of Cardiovascular Computed Tomography (SCCT)•AI/ML Toolkit AI and Innovations SymposiumFor more thought-provoking discussions on AI and machine learning in cardiac imaging, join us at the SCCT2026 AI and Innovations Symposium on July 9, 2026, where global experts will explore cutting-edge advances, real-world challenges and the future integration of AI into clinical practice.

In this episode, we explore the rapidly evolving field of regenerative medicine, focusing on a cutting-edge approach known as RPA (Regenerative Protein Array). Joined by leading medical experts, we break down how RPA differs from traditional therapies like PRP and stem cells, and how it leverages a complex network of proteins to support healing, recovery, and performance. The discussion covers real-world applications across elite athletes, aging populations, and neurocognitive conditions, while also addressing key questions around treatment frequency, safety, and effectiveness. Overall, this episode bridges the gap between emerging science and practical outcomes in modern regenerative care.Relevant links:Genesis Contact Information1-855-320-7559www.genesisregenerative.compatient-inquiry@genesisregenerative.comclinician-inquiry@genesisregenerative.com Dr. Jacobson Contact InformationMark Jacobson, M.D.Genesis Medical Director – MusculoskeletalMedical Imaging & Therapeutics, Lady Lake, FloridaFounder & Medical Directorwww.mitflorida.comDr. Bregman Contact InformationPeter Bregman, DPMGenesis Medical Director – Foot, Ankle, NeuropathyBregman Foot-Ankle & Nerve Center, Las Vegas, NVFounder & Medical Directorwww.bregmanfance.com Prof. Dr. Bankole Johnson Contact InformationProfessor Bankole Johnson,DSc, MD, MBChB, MPhil, DFAPA, FRCPysch, DAASCPGenesis Medical Director – Neuro & CognitiveMiami Stem Cell Clinic, Miami, FLFounder & Medical Directorwww.miamistemcell.clinicDisclaimer:The information provided in this podcast episode is for entertainment purposes and is NOT MEDICAL ADVICE. If you have any questions about your health, contact a medical professional. This content is strictly the opinions of Lucas Aoun and is for informational and entertainment purposes only. It is not intended to provide medical advice or to take the place of medical advice or treatment from a personal physician. All viewers of this content are advised to consult with their doctors or qualified health professionals regarding specific health questions. Neither Lucas Aoun nor the publisher of this content takes responsibility for possible health consequences of any person or persons reading or following the information in this content. All consumers of this content especially taking prescription or over-the-counter medications should consult their physician before beginning any nutritional, supplement or lifestyle program.Timestamps 0:00 Intro0:52 Meet the Experts3:53 What is RPA?6:14 Limits of Current Treatments12:41 Steroids vs Healing13:42 Athletes vs Everyday Recovery16:50 Brain and Neuro Cases24:32 Evidence and Ethics25:57 Real Patient Results30:55 Autoimmune Effects32:10 Rapid Injury Recovery33:50 Avoiding Surgery Case35:50 How RPA is Delivered36:35 Broader Applications49:52 Vision Applications51:01 Safety vs Other Treatments56:00 Outro Hosted on Acast. See acast.com/privacy for more information.

In this podcast, experts Hope S. Rugo, MD, FASCO; Giuseppe Curigliano, MD, PhD; Paolo Tarantino, MD, PhD; and Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS; discuss and debate recently published results of pivotal clinical trials in early-stage, HER2-positive breast cancer and their implications for patient care.

For many women, a history of breast cancer has meant an automatic “no” when it comes to menopausal hormone therapy. But is the story really that simple? In this video, we explore a more nuanced and evolving conversation—one grounded in decades of research, including the work of Avrum Z. Bluming, MD, and other leading experts who have closely examined the data on hormone therapy after breast cancer. Across multiple studies and reviews spanning over 40 years, the evidence paints a more complex picture. While certain risks—such as thromboembolism with oral formulations—are well documented, the long-held belief that hormone therapy universally increases breast cancer recurrence or mortality is increasingly being questioned. In fact, most studies have not shown an increase in breast cancer–related death, and only one trial demonstrated a limited increase in local (not distant) recurrence. At the same time, menopausal hormone therapy remains the most effective treatment for symptoms that deeply affect quality of life—while also offering potential benefits for cardiovascular health, bone strength, cognitive function, and longevity. So where does this leave us? This video is not about giving a one-size-fits-all answer. It's about encouraging thoughtful, informed decision-making. It's about moving beyond fear-based assumptions and toward individualized care—where risks and benefits are carefully weighed, and where women feel empowered to ask questions, seek multiple perspectives, and have meaningful conversations with their physicians. Because the most important takeaway is this: you deserve to be fully informed. Resources: Hormone Replacement Therapy After Breast Cancer: It Is Time Avrum Z. Bluming, MD LINK - https://bit.ly/4st0uji Menopausal Hormone Therapy for Breast Cancer Patients: What Is the Current Evidence? Sarah Glynne, MBBS, MSc, MRCP, MRCGP; James Simon, MD; Anthony Branson, FRCP; Stephen Payne, FRCS; Louise Newson, MBChB; Isaac Manyonda, PhD; Susan Cleator, PhD; Michael Douek, MD; Sasha Usiskin, MRCP; Jeffrey S. Tobias, MD; Jayant S. Vaidya, PhD LINK - https://bit.ly/41leKyt

In this episode Dr. Simon Ruffell joins to discuss the research on ayahuasca for PTSD. Dr. Ruffell is a psychiatrist, researcher, and student of curanderismo (Amazonian shamanism) working at the intersection of Western psychiatry, traditional plant medicine, and Indigenous knowledge systems. He is Executive Director of Onaya, Lecturer in Psychology and Psychedelics at the University of Exeter, and Chief Medical Officer of MINDS, with a focus on integrative and relational approaches to healing and consciousness. In this conversation, Dr. Ruffell explores the emerging research on ayahuasca as a treatment for PTSD, drawing on both Western scientific models and Indigenous Shipibo knowledge systems. He outlines how ayahuasca may work through mechanisms such as increased neuroplasticity, disruption of rigid predictive models, and potential epigenetic shifts related to stress and trauma, while emphasizing that these biological explanations exist alongside Indigenous understandings of "cleaning ancestral lines." Sharing preliminary findings from his ongoing research with military veterans in collaboration with Heroic Hearts Project, Dr. Ruffell discusses significant reductions in PTSD symptoms at six-month follow-up, the powerful role of community and ceremony, and the ethical complexities of studying sacred practices through Western scientific tools. He closes with a moving story of a veteran whose healing journey illustrates both the promise and the limits of psychedelic medicine when embedded in relational and cultural context.   In this episode, you'll hear: Western scientific theories for how ayahuasca may alleviate PTSD How trauma-related epigenetic changes may be transmitted across generations Preliminary results from Dr. Ruffell's study of ayahuasca for veterans diagnosed with PTSD The role of community bonding and peer support among veterans in maintaining therapeutic gains Why ayahuasca research in the Amazon includes a broader plant-based healing system—not just the brew itself How Indigenous healers interpret epigenetic findings as confirmation of longstanding ancestral frameworks The ethical considerations of bringing Western measurement tools (like EEG) into sacred ceremonial contexts   Quotes: "This is what I find most interesting about our research—that it is cutting edge science but at the same time, when we conduct it with indigenous healers, we get a whole new perspective on what could be happening when it comes to interpreting the results and also making decisions of what to research as well." [14:09] "According to measures of PTSD on the scales that we're looking at, over 80% of the participants that were scoring for PTSD before their ayahuasca retreats and no longer scoring for PTSD at that six month follow up. So it's not just immediately after the ayahuasca retreats. It's six months later. And that's super, super encouraging." [15:52] "When we take things to the lab, one of the reasons that we might see the effect size diminishing is because we no longer have shamanism, basically, which is exerting a huge effect." [16:55] "Traditionally what would happen is that the curandero would drink ayahuasca and the participants would just be there and the curandero would use the visions that they had with ayahuasca to look into the participants and to diagnose them. And then the healing would come through them singing their medicinal chants, which are the icaros. And then afterwards they would give them a prescription of plants or whatever it is that they needed. And sometimes the prescription would be to drink ayahuasca, but most of the time it wouldn't be. [27:18] "You can't separate like DMT, in my eyes, from the rest of the compounds in ayahuasca, from the ceremony, from the jungle. That, in my opinion, is what makes up Shipibo. Otherwise you just have a bunch of chemicals." [28:20]   Links: Dr. Ruffell's website Dr. Ruffell on LinkedIn Dr. Ruffell on Instagram Onaya website Onaya Science website Onaya on LinkedIn Onaya on Instagram Previous episode: Can Ayahuasca Heal PTSD? with Former Army Ranger Jesse Gould Psychedelic Medicine Association Porangui

Anne Walling, MB ChB, joins the Faculty Factory Podcast this week to discuss some incredible stories of resilience she uncovered while researching her new book "Women in Medicine: Stories from the Girls in White." Dr. Walling interviewed 37 women who fought for credibility, worked harder than is almost imaginable, and graduated from medical school between 1948 and 1975. She wanted to learn why they went into medicine and how their experiences unfolded throughout medical school, residency, and entry into practice. The work was conducted by Dr. Walling as formal qualitative research with IRB oversight and open-ended questions. She joined us at the Faculty Factory for her second interview on our show to share the stories and insights she gathered. You can learn more about the book here: https://www.routledge.com/Women-in-Medicine-Stories-from-the-Girls-in-White/Walling/p/book/9781032873190 Dr. Walling is Professor Emerita at the University of Kansas School of Medicine—Wichita and is also the author of "Academic Promotion for Clinicians: A Practical Guide to Promotion and Tenure in Medical Schools." Learn about that book here: https://link.springer.com/book/10.1007/978-3-031-84036-4 As mentioned, this is her second appearance on our show. You can listen to her first appearance “Episode 334 – A Deep Exploration of Academic Promotions for Clinicians with Anne Walling, MB ChB,” here: https://facultyfactory.org/anne-walling/

David Kavanagh, MBChB, PhD, FRCP - A Clinically Considered Real-World Case Series: Practice Essentials From Biopsy To Diagnosis in Immune-Mediated Glomerular Diseases

David Kavanagh, MBChB, PhD, FRCP - A Clinically Considered Real-World Case Series: Practice Essentials From Biopsy To Diagnosis in Immune-Mediated Glomerular Diseases

Alice Sheridan, MD, FASN, Jean Francis, MD, FASN, and Martina McGrath, MBChB, FASN, interview editors Klement Yeung, MD, and Christopher T. Chan, MD on nephSAP editorial "It's Time for Home Hemodialysis to be Treated as an Established Dialysis Modality."

Alice Sheridan, MD, FASN, Jean Francis, MD, FASN, and Martina McGrath, MBChB, FASN, interview editors Klement Yeung, MD, and Christopher T. Chan, MD on nephSAP editorial "It's Time for Home Hemodialysis to be Treated as an Established Dialysis Modality."

Melanie J. Davies, CBE, MBChB, MD, FMedSci / Linong Ji, MD - Managing the Cost of Type 2 Diabetes: The Impact of Effective Use of Established Therapies

Melanie J. Davies, CBE, MBChB, MD, FMedSci / Linong Ji, MD - Managing the Cost of Type 2 Diabetes: The Impact of Effective Use of Established Therapies

Melanie J. Davies, CBE, MBChB, MD, FMedSci / Linong Ji, MD - Managing the Cost of Type 2 Diabetes: The Impact of Effective Use of Established Therapies

Tune into this podcast to revisit discussions led by global experts, Karine Lacombe, MD, PhD, and Chloe Orkin, MBChB, FRCP, MD, featuring the latest updates on HIV treatment and prevention from the 2025 IDWeek and EACS conferences.Topics covered include:Real-world safety and efficacy of long-acting ARTART switch: preferences, treatment satisfaction, changes in weight and metabolic parameters, and HBV reactivation riskInvestigational therapiesUpdates on long-acting PrEP: persistence, use in people with substance use disorder, and coadministration with gender-affirming hormone therapyHIV and STI screening with PrEPSTI prevention To download the accompanying slides, visit the program page for this episode:https://bit.ly/3MGvegMPresenters:Karine Lacombe, MD, PhDProfessor of MedicineSorbonne UniversityHead of Infectious Diseases UnitSt Antoine Hospital, AP-HPParis, FranceChloe Orkin, MBChB, FRCP, MDProfessor of Infection and InequitiesDean for Healthcare TransformationQueen Mary University of LondonFaculty of Medicine and DentistryHonorary Consultant PhysicianBarts Health NHS TrustLondon, United KingdomGet access to all of our new episodes by subscribing to the Decera Clinical Education Infectious Diseases Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Fear of virologic failure is a major barrier to ensuring that people living with virally suppressed HIV are receiving the most optimal antiretroviral therapy (ART) regimen for them. Stream this Medical Minute to learn more about key guideline recommendations regarding ART switch and reassuring clinical data regarding efficacy, tolerability, and quality of life associated with switching a suppressive ART regimen. Topics covered include:Efficacy of switching to 2-drug oral ART: real-world evidenceReal-world analyses of virologic failure with switch to long-acting cabotegravir plus rilpivirinePatient selection to reduce risk of virologic failure with switch Regimen-specific switch considerationsPresenters:Dima Dandachi, MD, MPH, FIDSA, FACPAssociate Professor of MedicineDivision of Infectious DiseasesUniversity of MissouriMedical DirectorHIV Treatment and Prevention Program, MUHCMedical DirectorBoone County Public Health and Human ServicesColumbia, MissouriChloe Orkin, MBChB, FRCP, MDProfessor of Infection and InequitiesDean for Healthcare TransformationQueen Mary University of LondonFaculty of Medicine and DentistryHonorary Consultant PhysicianBarts Health NHS TrustLondon, United KingdomLink to full program and accompanying slides:https://bit.ly/3KPN0xbGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Interview with Darren Shu Jeng Ting, MBChB, PhD, author of Performance of Foundation Models vs Physicians in Textual and Multimodal Ophthalmological Questions. Hosted by Neil Bressler, MD. Related Content: Performance of Foundation Models vs Physicians in Textual and Multimodal Ophthalmological Questions Mastering Ophthalmology in the Digital Age

Alice M. Turner, MBChB, PhD - Cross-Talk Between Lung and Liver in Alpha-1 Antitrypsin Deficiency: A Call for Integrated Care

In this insightful episode, Dr. Bruce Hoffman discusses the intricacies of modern medicine, the importance of understanding the human body's response to environmental stressors, and the future of healthcare. Dr. Hoffman shares his journey and the development of his New Medical Curriculum, which emphasizes a holistic approach to health and healing.